A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

PHASE2RecruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

November 30, 2027

Conditions

Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

DRUG

APL-3007, pegcetacoplan (APL-2)

Complement C3 inhibitor

DRUG

APL-3007, pegcetacoplan (APL-2)

Complement C3 Inhibitor

OTHER

Placebo, Syfovre

Complement C3 Inhibitor

Trial Locations (2)

RECRUITING

Cumberland Valley Retina Consultants (CVRC), Hagerstown

RECRUITING

Bay Area Retina Associates - Walnut Creek, Walnut Creek